← ANALYST RATINGS · TIPRANKS
OmniAb (OABI): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $8.33, the highest $11.00, the lowest $5.00. The average is +81.6% from the last price of $4.59.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.50 → $5.00+11.1% | Hold | +8.9% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $5.00+11.1% | Hold | +8.9% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $5.00+11.1% | Hold | +8.9% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 → $5.00−9.1% | Hold | +8.9% | Reiterated | 08.10.26on TipRanks 03:05 | — | |
| Unknown Analyst | Leerink Partners | $10.00 → $12.00+20.0% | Buy | +161.4% | Reiterated | 07.10.26on TipRanks Oct 8 03:05 | +5.1%next day +2.6% · 5 days +0.8% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $9.00 | Buy | +96.1% | Reiterated | 07.10.26on TipRanks 07:31 | +5.1%next day +2.6% · 5 days +0.8% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $11.00 | Buy | +139.7% | Reiterated | 07.10.26on TipRanks 06:35 | +5.1%next day +2.6% · 5 days +0.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 → $5.00−9.1% | Hold | +8.9% | Reiterated | 04.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 | Hold | +8.9% | Reiterated | 30.09.26on TipRanks 19:05 | — | |
| Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% | Craig-Hallum | — | Buy | — | Reiterated | 29.09.26on TipRanks Sep 30 05:45 | +0.2%next day +4.8% · 5 days −10.2% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | — | Buy | — | Reiterated | 18.08.26on TipRanks 08:25 | +3.3%next day +6.7% · 5 days +19.1% | ↗ |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $3.00 → $5.00+66.7% | Buy | +8.9% | Reiterated | 17.08.26on TipRanks 11:26 | +13.5%next day +3.3% · 5 days +24.5% | ↗ |
| Robert Wasserman★★★★★★★★★★#2200 · hits 44% · avg +9.2% | Benchmark Co. | $6.00 → $4.00−33.3% | Buy | −12.9% | Reiterated | 06.11.25on TipRanks 09:25 | −1.7%next day −0.1% · 5 days +9.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering OmniAb
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $8.33 at a price of $4.96 (+68.0%); now: $9.25 at $4.59 (+101.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 3 | 3 | 5 | 6 | 8 |
| Buy | 5 | 1 | 1 | 5 | 7 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 30.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.14 to $-0.11). Last quarter: $-0.05.
Sales
Next quarter’s sales estimate — $3M (from $3M to $4M). Last quarter: $13M.
Best top-analyst consensus in the sector · Healthcare
About OmniAb
- CEO: Matthew W. Foehr
- Employees: 89
- 5980 Horton Street, EmeryVille, CA, 94608, US
- www.omniab.com
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗